Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock ...

Illumina (ILMN) stock downgraded to Sell while Charles River (CRL) stock and Hologic (HOLX) stock were upgraded to buy at Citi. Read more here.

Investing.com -- Illumina (NASDAQ: ILMN) stock declined 3.8% Wednesday after Citi downgraded the genomic sequencing company to Sell from Neutral, citing concerns about its second-half outlook.

In the assessment of 12-month price targets, analysts unveil insights for Illumina, presenting an average target of $105.18, a high estimate of $185.00, and a low estimate of $77.00. Observing a ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader ...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA ...

Plants produce a wide diversity of compounds. Broadly, these are separated into primary metabolites, which are necessary for ...

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...